Neoadjuvant Bevacizumab Plus Docetaxel/Cisplatin/Capecitabine Chemotherapy in Locally Advanced Gastric Cancer Patients: A Pilot Study

BACKGROUND: Bevacizumab (BEV) plus chemotherapy as a neoadjuvant regimen presents good efficacy in patients with locally advanced cancer. However, its role in patients with locally advanced gastric cancer (LAGC) is not clear. Thus, the study aimed to assess the efficacy and safety of neoadjuvant BEV...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Deguo, Wang, Zhenfeng, He, Tingbang, Yang, Lijun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Surgery
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9130594/
https://www.ncbi.nlm.nih.gov/pubmed/35647008
http://dx.doi.org/10.3389/fsurg.2022.842828

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9130594/
https://www.ncbi.nlm.nih.gov/pubmed/35647008
http://dx.doi.org/10.3389/fsurg.2022.842828

Ejemplares similares